DNA logo

Ginkgo Bioworks Holdings, Inc. (DNA)

Profile

Full Name

Ginkgo Bioworks Holdings, Inc.

Ticker

NYSE: DNA

Exchange

NYSE

Sector

Healthcare

Industry

Biotechnology

Country

United States

IPO

April 19, 2021

Indexes

Not included

Website

https://www.ginkgo.bio

Employees

834

Key Details

Price

$11.07(+4.14%)

Market cap

$655.34M(Small cap)

Last Dividend

-

TTM Dividend yield

-

Annual revenue

$227.04M(-9.71% YoY)

Annual EPS

$0.00(0.00% YoY)

PE ratio

-

Next earnings date

Nov 10, 2025

Next ex-dividend date

N/A

Next split date

N/A

Quick Search

    Add series to chart(max: 6)
    company, ETF, index, featured screener or watchlist
    series name
    See Full Chart & Historical Data

    Analyst ratings

    Price

    Add series to chart(max: 6)
    company, ETF, index, featured screener or watchlist
    series name
    Suggested series

    Current Price

    $11.07
    DNA price is $11.07

    30-Day Relative Volume

    1.07
    DNA 30-day relative volume is 1.07

    Price Performance

    Price Today change

    +4.14%
    DNA price is up +4.14% today

    Price YTD change

    +12.73%
    DNA price is up +12.73% since January 1st

    Price 1-year change

    +62.56%
    DNA price is up +62.56% year-on-year

    Price 3-year change

    -90.74%
    DNA price is down -90.74% over the past 3 years

    Price Range

    Price All-time high

    $634.56
    DNA price is currently -98.26% below its historical high of $634.56

    Price 3-year low

    $5.00
    DNA price is currently +121.40% above its 3-year low

    Capitalization

    Add series to chart(max: 6)
    company, ETF, index, featured screener or watchlist
    series name
    Suggested series

    Market cap

    Market cap

    $655.34M
    DNA market capitalization is $655.34 million

    Market cap 3-year change

    -88.31%
    DNA market capitalization is down -88.31% over the past 3 years

    Market cap All-time high

    $788.86B
    DNA market capitalization is currently -99.92% below its historical high of $788.86 billion

    Market cap sector rank

    67.28%
    DNA market capitalization is higher than 67.28% of companies in Healthcare sector

    Shares Outstanding

    Shares Outstanding 1-Year Change

    +6.52%
    DNA shares outstanding is up +6.52% year-on-year

    Shares Outstanding 3-Year Change

    +26.27%
    DNA shares outstanding is up +26.27% over the past 3 years

    Technical Indicators

    Add series to chart(max: 6)
    company, ETF, index, featured screener or watchlist
    series name
    Suggested series

    Beta

    2.04
    DNA beta is 2.04

    200-day SMA

    $9.87
    DNA price is currently +12.21% above its 200-day simple moving average

    50-day SMA

    $11.95
    DNA price is currently -7.34% below its 50-day simple moving average

    RSI

    47.45
    DNA 14-day relative strength index is 47.45

    Volume

    1.07
    DNA 30-day relative volume is 1.07

    ATR

    $0.91
    DNA average true range is $0.91

    10-day Historical Volatility

    57.95%
    DNA 10-day historical volatility is 57.95%

    Dividend

    Income Statement

    Add series to chart(max: 6)
    company, ETF, index, featured screener or watchlist
    series name
    Suggested series

    Revenue

    Revenue

    $227.04M
    DNA annual revenue is $227.04 million

    Revenue Analysts estimate

    $177.07M
    DNA annual revenue is currently +28.22% higher than the consensus analysts' forecast

    Revenue 1-year change

    -9.71%
    DNA annual revenue is down -9.71% year-on-year

    Revenue Sector rank

    75.29%
    DNA annual revenue is higher than 75.29% of companies in Healthcare sector

    EPS

    EPS

    $0.00
    DNA annual earnings per share is $0.00

    EPS Analysts estimate

    -$5.25
    DNA annual earnings per share is currently -100.00% lower than the consensus analysts' forecast

    EPS 1-year change

    0%
    DNA annual earnings per share has remained unchanged year-on-year

    EPS Sector rank

    82.45%
    DNA annual earnings per share is higher than 82.45% of companies in Healthcare sector

    Profit

    Gross profit

    $182.50M
    DNA annual gross profit is $182.50 million

    Gross margin

    60.55%
    DNA annual gross profit margin is 60.55%

    Operating profit

    -$487.73M
    DNA annual operating income is -$487.73 million

    Operating margin

    -214.82%
    DNA annual operating profit margin is -214.82%

    Net income

    -$547.03M
    DNA annual net profit is -$547.03 million

    Net margin

    -240.94%
    DNA annual net profit margin is -240.94%

    Expenses

    Total expenses

    $714.77M
    DNA annual total expenses is $714.77 million

    Operating expenses

    $670.22M
    DNA annual total operating expenses is $670.22 million

    Cost of goods sold

    $89.57M
    DNA annual cost of goods sold is $89.57 million

    Selling, general & administrative expenses

    $246.16M
    DNA annual SGA is $246.16 million

    Depreciation and amortization

    $63.02M
    DNA annual depreciation & amortization is $63.02 million

    Interest expense

    $94.00K
    DNA annual interest expense is $94.00 thousand

    Income tax

    -$479.00K
    DNA annual income tax is -$479.00 thousand

    EBIT & EBITDA

    EBIT

    -$547.41M
    DNA annual earnings before interest & taxes is -$547.41 million

    EBITDA

    -$484.39M
    DNA annual EBITDA is -$484.39 million

    Balance Sheet

    Add series to chart(max: 6)
    company, ETF, index, featured screener or watchlist
    series name
    Suggested series

    Assets

    Total assets

    $1.38B
    DNA annual total assets is $1.38 billion

    Non current assets

    $774.71M
    DNA annual long term assets is $774.71 million

    Current assets

    $602.74M
    DNA annual total current assets is $602.74 million

    Cash and cash equivalents

    $567.41M
    DNA annual cash & cash equivalents is $567.41 million

    Accounts receivable

    $22.44M
    DNA annual accounts receivable is $22.44 million

    Inventory

    $0.00
    DNA annual inventory is $0.00

    Liabilities

    Total liabilities

    $661.39M
    DNA annual total liabilities is $661.39 million

    Long term liabilities

    $554.13M
    DNA annual total long term liabilities is $554.13 million

    Current liabilities

    $107.27M
    DNA annual total current liabilities is $107.27 million

    Accounts payable

    $14.17M
    DNA annual accounts payable is $14.17 million

    Debt

    Total debt

    $467.73M
    DNA annual total debt is $467.73 million

    Total debt 1-year change

    +93.46%
    DNA annual total debt is up +93.46% year-on-year

    Long term debt

    $438.77M
    DNA annual long term debt is $438.77 million

    Short term debt

    $28.96M
    DNA annual short term debt is $28.96 million

    Equity & Capital

    Shareholders equity

    $716.06M
    DNA annual stockholders equity is $716.06 million

    Book value

    $716.06M
    DNA annual book value is $716.06 million

    Retained earnings

    -$5.84B
    DNA annual retained earnings is -$5.84 billion

    Working capital

    $495.48M
    DNA annual working capital is $495.48 million

    Cash Flow Statement

    Add series to chart(max: 6)
    company, ETF, index, featured screener or watchlist
    series name
    Suggested series

    Cashflow Activities

    Cash from operations

    -$319.58M
    DNA annual cash flow from operations is -$319.58 million

    Cash from operations 1-year change

    -8.15%
    DNA annual cash flow from operations is down -8.15% year-on-year

    Cash from investing

    -$62.24M
    DNA annual cash flow from investing activities is -$62.24 million

    Cash from investing 1-year change

    +22.87%
    DNA annual cash flow from investing activities is up +22.87% year-on-year

    Cash from financing

    -$1.74M
    DNA annual cash flow from financing activities is -$1.74 million

    Cash from financing 1-year change

    +45.93%
    DNA annual cash flow from financing activities is up +45.93% year-on-year

    CAPEX

    CAPEX

    $62.54M
    DNA annual capital expenditures is $62.54 million

    CAPEX 1-year change

    +53.28%
    DNA annual capital expenditures is up +53.28% year-on-year

    Free Cash Flow

    Free cash flow

    -$382.13M
    DNA annual free cash flow is -$382.13 million

    Free cash flow 1-year change

    -13.63%
    DNA annual free cash flow is down -13.63% year-on-year

    Profitability Ratios

    Add series to chart(max: 6)
    company, ETF, index, featured screener or watchlist
    series name
    Suggested series

    Margins

    Gross margin

    60.55%
    DNA annual gross profit margin is 60.55%

    Operating margin

    -214.82%
    DNA annual operating profit margin is -214.82%

    Net margin

    -240.94%
    DNA annual net profit margin is -240.94%

    ROA & ROE

    ROA

    -35.96%
    DNA annual return on assets is -35.96%

    ROE

    -60.34%
    DNA annual return on equity is -60.34%

    Valuation

    Add series to chart(max: 6)
    company, ETF, index, featured screener or watchlist
    series name
    Suggested series

    PE Ratio

    PE ratio

    -
    DNA price to earnings ratio value is unknown

    PE ratio Sector rank

    -
    DNA price to earnings ratio is unknown

    PB Ratio

    PB ratio

    1.07
    DNA price to book ratio is 1.07

    PB ratio Sector rank

    36.5%
    DNA price to book ratio is higher than 36.5% of companies in Healthcare sector

    PS Ratio

    PS ratio

    2.84
    DNA price to sales ratio is 2.84

    PS ratio Sector rank

    44.31%
    DNA price to sales ratio is higher than 44.31% of companies in Healthcare sector

    Enterprise value

    Enterprise value

    $599.53M
    DNA enterprise value is $599.53 million

    Enterprise value Sector rank

    67.85%
    DNA enterprise value is higher than 67.85% of companies in Healthcare sector

    EV/EBITDA

    EV/EBITDA

    -2.05
    DNA EV/EBITDA is -2.05

    EV/EBITDA Sector rank

    36.14%
    DNA EV/EBITDA is higher than 36.14% of companies in Healthcare sector

    Financial Health

    Add series to chart(max: 6)
    company, ETF, index, featured screener or watchlist
    series name
    Suggested series

    Liquidity

    Current ratio

    5.62
    DNA annual current ratio is 5.62

    Quick ratio

    5.62
    DNA annual quick ratio is 5.62

    Leverage

    Debt to equity

    0.65
    DNA annual debt to equity ratio is 0.65

    Interest coverage ratio

    -5823.55
    DNA annual interest coverage ratio is -5823.55

    Risk & Stability

    Piotroski F-Score

    4
    DNA piotroski f-score is 4

    Altman Z-Score

    -6.05
    DNA altman z-score is -6.05

    Analyst ratings

    Recent major analysts updates

    Aug 25, 25 BTIG
    Sell
    Sep 20, 24 TD Cowen
    Buy
    Aug 23, 24 BTIG
    Sell
    Jul 9, 24 Goldman Sachs
    Sell
    Jun 26, 24 BTIG
    Sell
    May 15, 24 Morgan Stanley
    Equal-Weight
    May 15, 24 BTIG
    Sell
    May 10, 24 William Blair
    Underperform
    Mar 1, 24 TD Cowen
    Outperform
    Jan 23, 24 Goldman Sachs
    Sell

    Institutional Ownership

    Screeners with DNA included

    Growing Shares Outstanding
    US stocks
    Stocks with high beta
    Stocks recommended to hold
    Best performing stocks last 3 months
    Healthcare sector
    All stocks
    Stocks above analysts price target
    Best performing stocks last 12 months
    Biotech Companies
    • What is the ticker symbol for Ginkgo Bioworks Holdings, Inc.?
    • Does Ginkgo Bioworks Holdings, Inc. pay dividends?
    • What sector is Ginkgo Bioworks Holdings, Inc. in?
    • What industry is Ginkgo Bioworks Holdings, Inc. in?
    • What country is Ginkgo Bioworks Holdings, Inc. based in?
    • When did Ginkgo Bioworks Holdings, Inc. go public?
    • Is Ginkgo Bioworks Holdings, Inc. in the S&P 500?
    • Is Ginkgo Bioworks Holdings, Inc. in the NASDAQ 100?
    • Is Ginkgo Bioworks Holdings, Inc. in the Dow Jones?
    • When was Ginkgo Bioworks Holdings, Inc.'s last earnings report?
    • When does Ginkgo Bioworks Holdings, Inc. report earnings?

    What is the ticker symbol for Ginkgo Bioworks Holdings, Inc.?

    The ticker symbol for Ginkgo Bioworks Holdings, Inc. is NYSE:DNA

    Does Ginkgo Bioworks Holdings, Inc. pay dividends?

    No, Ginkgo Bioworks Holdings, Inc. does not pay dividends

    What sector is Ginkgo Bioworks Holdings, Inc. in?

    Ginkgo Bioworks Holdings, Inc. is in the Healthcare sector

    What industry is Ginkgo Bioworks Holdings, Inc. in?

    Ginkgo Bioworks Holdings, Inc. is in the Biotechnology industry

    What country is Ginkgo Bioworks Holdings, Inc. based in?

    Ginkgo Bioworks Holdings, Inc. is headquartered in United States

    When did Ginkgo Bioworks Holdings, Inc. go public?

    Ginkgo Bioworks Holdings, Inc.'s initial public offering (IPO) was on April 19, 2021

    Is Ginkgo Bioworks Holdings, Inc. in the S&P 500?

    No, Ginkgo Bioworks Holdings, Inc. is not included in the S&P 500 index

    Is Ginkgo Bioworks Holdings, Inc. in the NASDAQ 100?

    No, Ginkgo Bioworks Holdings, Inc. is not included in the NASDAQ 100 index

    Is Ginkgo Bioworks Holdings, Inc. in the Dow Jones?

    No, Ginkgo Bioworks Holdings, Inc. is not included in the Dow Jones index

    When was Ginkgo Bioworks Holdings, Inc.'s last earnings report?

    Ginkgo Bioworks Holdings, Inc.'s most recent earnings report was on August 7, 2025

    When does Ginkgo Bioworks Holdings, Inc. report earnings?

    The next expected earnings date for Ginkgo Bioworks Holdings, Inc. is November 10, 2025
    On this page